Announcements Trials
Browse Landscape

Phase

Phase 1 22Phase 1/2 5Phase NA 3Phase 2 1

Status

Unknown 3Recruiting 2

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Other solid neoplasm 5

Conditions

Carcinoma, Non-Small-Cell Lung 699Breast Neoplasms 630Neoplasms 582Leukemia, Myeloid, Acute 481Colorectal Neoplasms 456Multiple Myeloma 444Melanoma 426Prostatic Neoplasms 383Neoplasm Metastasis 373Pancreatic Neoplasms 363Recurrence 350Lymphoma 340Ovarian Neoplasms 325Lung Neoplasms 297Lymphoma, Non-Hodgkin 295Leukemia 287Glioblastoma 275Precursor Cell Lymphoblastic Leukemia-Lymphoma 249Stomach Neoplasms 246Leukemia, Lymphocytic, Chronic, B-Cell 235Carcinoma, Hepatocellular 231Squamous Cell Carcinoma of Head and Neck 220Lymphoma, Large B-Cell, Diffuse 217Myelodysplastic Syndromes 212Carcinoma, Renal Cell 210Lymphoma, Follicular 183Head and Neck Neoplasms 172Brain Neoplasms 169Lymphoma, Mantle-Cell 167Triple Negative Breast Neoplasms 166

Interventions

Clinical Trials, Phase II as Topic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × Advanced Malignant Solid Tumors × Clear all
NCT06499350 2026-03-10

A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors

FindCure Biosciences (ZhongShan) Co., Ltd.

Phase 1/2 Recruiting
33 enrolled
Other solid neoplasm

Advanced Malignant Solid Tumors

NCT06464055 2025-02-10

A Study of GQ1010 in Subjects With Advanced Solid Tumors

GeneQuantum Healthcare (Suzhou) Co., Ltd.

Phase 1/2 Recruiting
260 enrolled
Other solid neoplasm

Advanced Malignant Solid Tumors

NCT05338957 2022-12-01

A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors.

Shanghai Miracogen Inc.

Phase 1/2 Unknown
30 enrolled
Other solid neoplasm

Advanced Malignant Solid Tumors

NCT05478785 2022-07-29

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Efficacy of Cisplatin Micelle Injection (HA132) in Patients With Advanced Malignant Solid Tumors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 1/2 Unknown
126 enrolled
Other solid neoplasm

Advanced Malignant Solid Tumors

NCT04226066 2020-12-07

Safety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC), in Patients With Advanced Malignant Solid Tumors

Tasly Tianjin Biopharmaceutical Co., Ltd.

Phase 1/2 Unknown
69 enrolled
Other solid neoplasm

Advanced Malignant Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡